Wes Kassouf
@WesKassouf
Followers
1K
Following
3K
Media
58
Statuses
1K
Professor, Urologic Oncology, McGill University Health Center. President, @CanUrolAssoc
Montreal, Canada
Joined June 2015
Very proud to share our seminal work @NatureComms on the role of #neutrophil extracellular traps in radioresistance for invasive #bladdercancer #organpreservation
3
11
63
0
7
27
@WesKassouf presenting #IBCN25 @IBCN1997 🇩🇪LEGEND trial prelim data 6mo pCR 47% for high risk NMIBC. Provocative study and another potential disruptive agent. 💫 @UTMBUrology @utmbhealth
1
2
8
#CUA26 is going to Saskatoon! Discover the greatness of this city and join us for an unforgettable meeting. Abstract submission opens: Oct 31, 2025 Deadline: Jan 11, 2026 Registration opens: Feb 2026 Info 👉 https://t.co/MHXBVl2MOi
#LetsGoSaskatooning
0
1
3
🧬 New hope for prostate cancer patients! A team at The Institute, led by Simone Chevalier, PhD & Armen Aprikian, MD, found genetic blood signatures to better predict disease risk. @cusm_muhc Learn more 👉 https://t.co/Oc9xA3KiST
0
2
5
Intravesical Gemcitabine via TAR200 for BCG - unresponsive NMIBC with CIS +/- papillary tumors is FDA approved. It joins a number of other agents with a spectrum of MOAs. With data generated from single arm trials there is not a clear winner.
6
64
161
📫 Interim results of #Sunrise4 are released @TheLancetOncol Neoadjuvant #TAR200 + cetrelimab vs cetrelimab monotherapy in pts with #MIBC ✅ TAR200+CET: pCR 42%, Major path Response 60% ✅ in cT2 pts baseline: pCR 48% ✅ TAR200 exposure-response association: pCR 50% if TAR200x4
3
54
142
Perioperative EVP shows ⬆️ EFS,OS & pCR vs cystectomy alone in high risk cisplatin ineligible MIBC (KN901). Highly active systemic vs surgery will rescue many patients with aggressive micrometastatic disease. CRs for EVP=30% in M1 but should be ⬆️ in MIBC https://t.co/MEsZvzktTe
6
78
210
Exploratory biomarker analyses of adjuvant #nivolumab in urothelial carcinoma from #CheckMate274 trial are out in @NatureMedicine @MattGalsky | 1. Pre-existing immune infiltration and T-cell infiltration is prognostic and predictive of adj Nivo benefit 2. Composite model
2
34
80
Breaking News from ph3 Embark trial👉Enzalutamide+ADT improve overall survival (OS) vs. ADT alone in Non-Metastatic HSPC #Prostatecancer Congrats to @SFreedlandMD @nealshore & team! Earlier enza works better! Link👉 https://t.co/nTWHrnnbTZ
@OncoAlert @urotoday @PCFnews
4
65
159
Cretostimogene expanded access program provides alternative for BCG-unresponsive #BladderCancer patients. @WesKassouf @mcgillu joins @zklaassen_md @GACancerCenter to discuss the expanded access program for cretostimogene grenadenorepvec in BCG-unresponsive non-muscle invasive
1
3
8
Truely humbled and honoured to serve as President of our amazing #CUA association ! I look forward to the year ahead, where we continue to grow, share knowledge, collaborate, and strengthen our bonds as a community @CanUrolAssoc @mcgillu
As CUA came to an end last night, we celebrated with a beautiful ceremony honoring exceptional members of the urological community in Canada. CONGRATULATIONS 🎊 to Dr. Wassim Kassouf, CUA 2025-2026 President! We look forward to seeing you all in 1 year in Saskatoon! @WesKassouf
17
4
78
0
5
15
Congrats to the @theNCI Team on this landmark paper in HLRCC! It sets the SOC in this rare kidney cancer variant. @NEJM @NCICCR_SurgOnc @nciccr_gmb
nejm.org
Hereditary leiomyomatosis and renal-cell cancer (HLRCC) is an inherited disorder characterized by germline pathogenic variants in the gene encoding fumarate hydratase and an increased risk of papil...
2
34
101
A 🧵 on our recent study on surveillance for IR-NMIBC @EurUrolOncol
https://t.co/trmFp9Yd0y There is limited evidence on follow-up for IR-NMIBC. We used data from >2000 primary Ta–T1 NMIBC to stratify IR-NMIBC by recurrence risk and propose a risk-adapted follow-up approach.
2
14
39
FDA approves UGN-102, mitomycin intravesical solution (ZUSDURI™ ) for Recurrent Low-Grade IR NMIBC https://t.co/GbjGQhgu68
@UroGenPharma @UrogerliMD @siadaneshmand @MaxKates @IBCG_BladderCA @joanfundi
businesswire.com
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty can...
FDA ODAC: 5–4 votes against UGN-102 in IR #NMIBC, and raises a critical point that even though data ‘looked good’, there are questions which can only be clarified via a well-designed RCT https://t.co/Jf0ew1Q0h0 via @CancerNetwrk @UrogerliMD @shilpaonc @IBCG_BladderCA
3
14
32
Thank you for the kind invitation….I had a terrific experience visiting your wonderful department!
Many thanks to @WesKassouf our visiting professor for this year’s The Ruth and Carmine T. Perrapato Visiting Professorship in Urologic Oncology @UVMUrology @UVMMedCenter We had a great time learning about the latest innovations and challenges in the management of bladder
0
0
19
Our recent publication in @EurUrolOncol demonstrates - for the first time -that an AI-powered histologic biomarker (CHAI) can predict response to intravesical BCG vs. gemcitabine/docetaxel in high-grade NMIBC. A critical step forward in precision intravesical therapy.
7
33
92
#CUAGuidelines you will not want to miss this one! Join us - registration is free>>> https://t.co/gNhm1Ivq2Y
@WesKassouf @kalasri3 @BladderCancerCA @WorldBladderCan #bladdercancer
0
1
10
@UroDocAsh @AmerUrological @pcvblack @WesKassouf @siadaneshmand @doctorjakeuro @VigneshPackiam @MarkTysonMD @ryansteinbergmd @WesKassouf Strong rationale and prospective data for NAI-BCG but we need to make more accessible worldwide #AUA25
@MRoupret @BogdanaSchmidt @drtanws @AmerUrological @urogeek
1
5
11
@IBCG_BladderCA @EUplatinum @siadaneshmand @pjhensley11 @nnavai @JanetKukreja @WesKassouf @DrRosenbergMSK @urotoday @SWilliams_MD @TomFlaigMD @BladderCancerUS @joanfundi @MarekBabjuk @paolo_gontero @LAUrology_NL @LauraBukavinaMD @SimaPorten @bbmdmsk @drjefstathiou @ACKoongMDPhD Partial cystectomy and radical TUR are not standard options - but may be considered in highly selected cases. IBCG emphasizes: 🔬 Path review by GU specialists 🧪 Use of blue light cystoscopy when available 🎯 Clear surgical margins 🧵4/5
1
7
14